| Outcome Measures: |
Primary: Compared with baseline data, the proportion of subjects reaching iPTH target at 20th week, blood test, 20 weeks|Compared with baseline data, the proportion of subjects reaching iPTH target at 32nd week, blood test, 32 weeks | Secondary: Compared with baseline data, the proportion of patients reaching Ca & P target simultaneously at 32nd week, blood test, 32 weeks|Compared with baseline data, the proportion of patients with ≥ 30% reduction in iPTH level at 20th week, blood test, 20 weeks|Compared with baseline data, the proportion of patients with ≥ 30% reduction in iPTH level at 32nd week, blood test, 32 weeks|The proportion of patients once reaching iPTH target during 1st~32nd week, blood test, 32 weeks|The proportion of patients once reaching iPTH target during 33rd~52nd week, blood test, 52 weeks|Compared with baseline data, the change of Ca × P at 20th week, blood test, 20 weeks|Compared with baseline data, the change of Ca × P at 32nd week, blood test, 32 weeks|Compared with baseline data, the change of alkaline phosphatase (ALP) at 20th week, blood test, 20 weeks|Compared with baseline data, the change of alkaline phosphatase (ALP) at 32nd week, blood test, 32 weeks|Compared with baseline data, the change of fibroblast growth factor 23(FGF23) at 20th week, blood test, 20 weeks|Compared with baseline data, the change of fibroblast growth factor 23(FGF23) at 32nd week, blood test, 32 weeks|Compared with baseline data, the adjustment (type or amount) of calcium agents at 20th week, medication evaluation, 20 weeks|Compared with baseline data, the adjustment (type or amount) of calcium agents at 32nd week, medication evaluation, 32 weeks|Compared with baseline data, the adjustment (type or amount) of phosphate binders at 20th week, medication evaluation, 20 weeks|Compared with baseline data, the adjustment (type or amount) of phosphate binders at 32nd week, medication evaluation, 32 weeks|Compared with baseline data, the adjustment (type or amount) of vitamin D and its analogues at 20th week, medication evaluation, 20 weeks|Compared with baseline data, the adjustment (type or amount) of vitamin D and its analogues at 32nd week, medication evaluation, 32 weeks|Compared with baseline data, the adjustment (type or amount) of diphosphonic acid salts at 20th week, medication evaluation, 20 weeks|Compared with baseline data, the adjustment (type or amount) of diphosphonic acid salts at 32nd week, medication evaluation, 32 weeks|Compared with the data at 32nd week, the proportional change of patients reaching iPTH target at 52nd week who continue Cinacalcet treatment during 20-week real world period, blood test, 52 weeks|Compared with the data at 32nd week, the proportional change of patients reaching iPTH target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period, blood test, 52 weeks|Compared with the data at 32nd week, the proportional change of patients reaching Ca target at 52nd week who continue Cinacalcet treatment after 20-week real world period, blood test, 52 weeks|Compared with the data at 32nd week, the proportional change of patients reaching Ca target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period, blood test, 52 weeks|Compared with the data at 32nd week, the proportional change of patients reaching P target at 52nd week who continue Cinacalcet treatment after 20-week real world period, blood test, 52 weeks|Compared with the data at 32nd week, the proportional change of patients reaching P target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period, blood test, 52 weeks|Compared with the data at 32nd week, the proportional change of patients reaching Ca × P target at 52nd week who continue Cinacalcet treatment after 20-week real world period, blood test, 52 weeks|Compared with the data at 32nd week, the proportional change of patients reaching Ca × P target at 52nd week who discontinue Cinacalcet treatment after 20-week real world period, blood test, 52 weeks|The dose change of calcium agents which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period, medication evaluation, 20 weeks|The dose change of phosphate binders which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period, medication evaluation, 20 weeks|The dose change of vitamin D and its analogues which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period, medication evaluation, 20 weeks|The dose change of diphosphonic acid salts which were used by patients for chronic kidney disease-mineral and bone disorder(CKD-MBD) treatment during 20-week real world period, medication evaluation, 20 weeks|The reasons of patients discontinuing Cinacalcet in 20-week real world, List presentation, 20 weeks
|
